OBJECTIVES: New treatments in oncology frequently imply in higher costs. Historically there is a lack of statistical data on cancer treatments in PHS in Brazil. Higher costs combined to lack of information may result in waste of resources. We present here real world data (RWD) on MM treatment collected from a dedicated database of cancer treatments Evidencias® (www.evidencias.com.br). METHODS: Between November of 2007 and October 2009 we retrieved all patients with MM registered on Evidencias®. Anthropometric data, staging, types of treatment, duration, and cost of chemotherapy and adjunctive therapies (AT) such as antiemetics, erythropoietin, colony stimulating factors and bisphosphonates were extracted. RESULTS: We identified 98 patients (53% women and 47% men). The mean body surface area (BSA) was1.73 m2. Staging was stratified as follows: 21% Stage I, 8% stage II and 54% stage III. In 17% of the cases stage information was unavailable. Total cost of drugs was US$1,709,404.50. Chemotherapy drugs represented US$1,214,275.03 (71%) of which 98% (US$1,192,849.98) were due to the use of Bortezomib and 29% (US$495,129.46) to AT. Bortezomib was present in 57% of the treatments either isolated (42%) or combined to other chemotherapy (15%). Cyclophosphamide was used in 20% of the treatments, Doxorubicin in 18% and Melphalan in 5%. Mean duration of treatment was 3.9 cycles of chemotherapy. CONCLUSIONS: Real world data although a fundamental tool to guide health care providers in the correct allocation of resources, is still rare in Brazil e Latin America. Bortezomib is used in 57% of MM treatments but represents 98% of chemotherapy costs.